Recce Pharmaceuticals Ltd (ASX:RCE)
Australia
· Delayed Price · Currency is AUD 0.2900
0.00 (0.00%)
Apr 30, 2025, 4:10 PM AEST
Recce Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Other Revenue | 9.59 | 5.03 | 4.37 | 3.08 | 1.64 | 1.12 | Upgrade
|
| Revenue | 9.59 | 5.03 | 4.37 | 3.08 | 1.64 | 1.12 | Upgrade
|
| Revenue Growth (YoY) | 42.20% | 15.19% | 41.50% | 88.41% | 45.97% | 65.05% | Upgrade
|
| Cost of Revenue | 10.81 | 7.22 | 7.41 | 6.33 | 5.7 | 2.1 | Upgrade
|
| Gross Profit | -1.22 | -2.19 | -3.05 | -3.25 | -4.07 | -0.98 | Upgrade
|
| Selling, General & Admin | 7.44 | 7.09 | 5.75 | 3.54 | 2.29 | 1.88 | Upgrade
|
| Other Operating Expenses | 7.53 | 7.34 | 3.53 | 2.42 | 1.63 | 1.17 | Upgrade
|
| Operating Expenses | 15.63 | 14.81 | 9.83 | 6.4 | 9.44 | 3.31 | Upgrade
|
| Operating Income | -16.85 | -17 | -12.88 | -9.65 | -13.51 | -4.29 | Upgrade
|
| Interest Expense | -1.3 | -0.84 | -0.18 | -0.01 | -0.01 | -0.06 | Upgrade
|
| Interest & Investment Income | 0.23 | 0.19 | 0.07 | 0.09 | 0.11 | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0 | -0.1 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -17.94 | -17.66 | -12.99 | -9.57 | -13.51 | -4.32 | Upgrade
|
| Legal Settlements | - | - | -0.08 | -1.42 | - | - | Upgrade
|
| Pretax Income | -17.94 | -17.66 | -13.08 | -10.99 | -13.51 | -4.32 | Upgrade
|
| Net Income | -17.94 | -17.66 | -13.08 | -10.99 | -13.51 | -4.32 | Upgrade
|
| Net Income to Common | -17.94 | -17.66 | -13.08 | -10.99 | -13.51 | -4.32 | Upgrade
|
| Shares Outstanding (Basic) | 195 | 177 | 174 | 174 | 155 | 127 | Upgrade
|
| Shares Outstanding (Diluted) | 195 | 177 | 174 | 174 | 155 | 127 | Upgrade
|
| Shares Change (YoY) | 7.17% | 1.79% | -0.09% | 12.05% | 22.17% | 34.65% | Upgrade
|
| EPS (Basic) | -0.09 | -0.10 | -0.08 | -0.06 | -0.09 | -0.03 | Upgrade
|
| EPS (Diluted) | -0.09 | -0.10 | -0.08 | -0.06 | -0.09 | -0.03 | Upgrade
|
| Free Cash Flow | -13.47 | -13.15 | -12.73 | -9.05 | -7.93 | -3.81 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | -0.07 | -0.07 | -0.05 | -0.05 | -0.03 | Upgrade
|
| Gross Margin | -12.69% | -43.52% | -69.83% | -105.22% | -248.40% | -87.13% | Upgrade
|
| Operating Margin | -175.65% | -338.12% | -295.00% | -312.74% | -824.91% | -382.10% | Upgrade
|
| Profit Margin | -186.95% | -351.24% | -299.58% | -356.12% | -825.30% | -384.83% | Upgrade
|
| Free Cash Flow Margin | -140.40% | -261.53% | -291.53% | -293.38% | -484.42% | -339.96% | Upgrade
|
| EBITDA | -16.78 | -16.94 | -12.83 | -9.6 | -13.39 | -4.24 | Upgrade
|
| EBITDA Margin | -174.91% | - | -293.92% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.07 | 0.07 | 0.05 | 0.05 | 0.12 | 0.05 | Upgrade
|
| EBIT | -16.85 | -17 | -12.88 | -9.65 | -13.51 | -4.29 | Upgrade
|
| EBIT Margin | -175.65% | - | -295.00% | - | - | - | Upgrade
|
| Revenue as Reported | 4.6 | - | - | - | - | - | Upgrade
|
| Advertising Expenses | - | 1.24 | 1.12 | 0.99 | 0.7 | 0.19 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.